Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Shaker R. Dakhil"'
Autor:
Michelle C. Janelsins, Jodi Geer, Charles Kamen, Allison Magnuson, Patrick M. Reagan, Mostafa R. Mohamed, Supriya G. Mohile, Luke J. Peppone, Charles E. Heckler, Marianne Melnik, Elizabeth Belcher, Gary R. Morrow, Tim A. Ahles, Shaker R. Dakhil, Lori M. Minasian
Publikováno v:
J Natl Cancer Inst
Background Cancer-related cognitive decline (CRCD) is an important clinical problem, but limited research exists on assessment of cognitive function in patients with lymphoma. Methods The overall objective of this nationwide, prospective, observation
Autor:
Ann M. O'Mara, Victor Kipnis, Jerry W. Mitchell, Amber S. Kleckner, Charles S. Kamen, Luke J. Peppone, AnnaLynn M Williams, Jodi Geer, Carly Paterson Khan, Karen Mustian, Shaker R. Dakhil, Michelle C Janelsins, C. E. Heckler, Mary Ontko, Debra L. Barton
Publikováno v:
Breast Cancer Res Treat
PURPOSE: Fatigue and anxiety are common and significant symptoms reported by cancer patients. Few studies have examined the trajectory of multidimensional fatigue and anxiety, the relationships between them and with quality of life. METHODS: Breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71bc9e6aa63c81a412fdbb765c252c79
https://europepmc.org/articles/PMC8080260/
https://europepmc.org/articles/PMC8080260/
Autor:
Sharon Wilks, Michael J. Klepper, Jeff Vacirca, C Taylor, Richy Agajanian, I. Schnadig, M. Mosier, Y. Payne, W Cooper, Shaker R. Dakhil
Publikováno v:
Cancer Research. 76:P1-10
Background:Managing delayed chemotherapy-induced nausea and vomiting (CINV) associated with HEC is an unmet need. AC-based HEC is often administered to breast cancer patients (pts), a mostly female, high-CINV-risk population. APF530, an extended-rele
Autor:
Anthony J. Scalzo, Charles E. Heckler, Gary R. Morrow, Luke J. Peppone, Oxana Palesh, Michelle C. Janelsins, Howard M. Gross, Karen M. Mustian, Claire C. Conley, Charles Kamen, Shaker R. Dakhil
Publikováno v:
Journal of Clinical Psychopharmacology. 36:82-85
The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients. The primary aim is to elucidate factors that contributed to the effec
Autor:
Sheila N. Garland, Anita R. Peoples, Peter Bushunow, Deborah Dudgeon, Jeffrey J. Kirshner, Marie Flannery, Joseph A. Roscoe, Gary R. Morrow, Judith O. Hopkins, Charles E. Heckler, Luke L. Peppone, Shaker R. Dakhil, Tarit K. Banerjee
Publikováno v:
Supportive Care in Cancer. 24:1339-1347
Cancer-related dyspnea is a common, distressing, and difficult-to-manage symptom in cancer patients, resulting in diminished quality of life and poor prognosis. Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has pr
Autor:
Danielle Awad, Frank L. Meyskens, Katherine D. Crew, Joseph M. Unger, Danika L. Lew, Lori M. Minasian, James L. Wade, Julie Gralow, Dawn L. Hershman, Shaker R. Dakhil, Cathee Till, Carol M. Moinpour, Heather Greenlee
Publikováno v:
Journal of Clinical Oncology. 33:1910-1917
Purpose Musculoskeletal symptoms are the most common adverse effects of aromatase inhibitors (AIs) and can result in decreased quality of life and discontinuation of therapy. Omega-3 fatty acids (O3-FAs) can be effective in decreasing arthralgia resu
Autor:
Debra L. Barton, Keren Sturtz, Thomas J. Smith, Daniel M. Anderson, Pamela J. Atherton, Haeseong Park, Rui Qin, Suneetha Puttabasavaiah, Shaker R. Dakhil, Kathleen A. Flynn, Charles L. Loprinzi, Gilbert D. A. Padula, Nguyet A. Le-Lindqwister
Publikováno v:
Menopause. 22:627-632
Objective Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life. Preliminary data suggested that magnesium might be used as an effective low-cost treatment of hot flashes with minimal adverse effects.
Autor:
Janine M. Lombard, Agustin A. Garcia, Halle C. F. Moore, Frances M. Boyle, Prudence A. Francis, Carol J. Fabian, Shaker R. Dakhil, Carlos S. Vallejos, John F. Forbes, Henry L. Gomez, Kathy S. Albain, David L. Porter, Ann H. Partridge, Silvana Martino, Gabriel N. Hortobagyi, Lori M. Minasian, Joseph M. Unger, Richard D. Gelber, Frank L. Meyskens, Lori J. Goldstein, Erika Hitre, Julie R. Gralow, Kelly-Anne Phillips, William E. Barlow
Publikováno v:
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. New England Journal of Medicine, 372(10), 923-932. doi: 10.1056/NEJMoa1413204. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/49n0z7zv
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Obstetrical and Gynecological Survey, 70(6), 392-393. doi: 10.1097/01.ogx.0000467230.21869.a4. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5d37s9m3
Moore, HCF; Unger, JM; Phillips, KA; Boyle, F; Hitre, E; Porter, D; et al.(2015). Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. Obstetrical and Gynecological Survey, 70(6), 392-393. doi: 10.1097/01.ogx.0000467230.21869.a4. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5d37s9m3
Copyright © 2015 Massachusetts Medical Society. BACKGROUND Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin- releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack
Autor:
James Bailen, Christopher Michael Pieczonka, Nicholas J. Vogelzang, Krista Van Velzen, Lawrence Karsh, Harini Kandadi, Shaker R. Dakhil, William R. Berry, Nadeem A. Sheikh
Publikováno v:
Journal of Clinical Oncology. 37:e16504-e16504
e16504 Background: Sipuleucel-T is an autologous cellular immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In IMPACT (NCT00065442), a phase 3 trial, sipuleucel-T-induced immune responses against
Autor:
Carl A. Olsson, Jeffrey L. Vacirca, Raoul S. Concepcion, Nancy N. Chang, Ian D. Schnadig, Bruce Brown, Ronald F. Tutrone, Andrew J. Armstrong, Shaker R. Dakhil, Hong Tang, Nicholas J. Vogelzang
Publikováno v:
Journal of Clinical Oncology. 37:177-177
177 Background: Managing patients ≥ 80 years old (yo) with mCRPC is challenging, given the high prevalence of comorbidities, polypharmacy, organ dysfunction, and reduced performance status (PS). Balancing treatment benefit with safety and quality o